Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PET-CT Based Radiotherapy in Esophageal Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Maastricht Radiation Oncology
ClinicalTrials.gov Identifier:
NCT01156831
First received: July 2, 2010
Last updated: December 5, 2014
Last verified: December 2014

July 2, 2010
December 5, 2014
November 2007
May 2011   (final data collection date for primary outcome measure)
Locoregional control [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01156831 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
  • Disease Free survival [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
  • Tumor regression grade [ Time Frame: At the time of surgery ] [ Designated as safety issue: No ]
    Tumor regression grade at time of surgery evaluated by pathologist.
Same as current
Not Provided
Not Provided
 
PET-CT Based Radiotherapy in Esophageal Cancer Patients
Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Primary Care Clinic

Esophageal Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
115
May 2013
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
  • Local curable disease able to undergo Chemoradiotherapy.

Exclusion Criteria:

  • Metastasized disease.
  • Previous or concurrent malignancies.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01156831
09-18-12/08
Yes
Maastricht Radiation Oncology
Maastricht Radiation Oncology
Not Provided
Principal Investigator: Guido Lammering, MD PhD Radiation Oncology, Maastro Clinic
Principal Investigator: Meindert Sosef, MD PhD Atrium Hospital Heerlen
Maastricht Radiation Oncology
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP